Your browser does not support JavaScript!
Google  

 

 

:::
[2015/01/12]Professor Wei-Ming Chen and His Team from TPEVGH Win a 17th National Biotechnology & Medical Care Quality Award

[2015/01/12]

Professor Wei-Ming Chen and His Team from TPEVGH Win a 17th National Biotechnology & Medical Care Quality Award

Doctor Wei-Ming Chen, Professor from the National Yang Ming University College of Medical and his team from Taipei Veterans General Hospital (TPEVGH) Musculoskeletal Oncology and Research Centre won a 17th National Biotechnology & Medical Care Quality Award--Silver medal in Featured Specialty Section, Hospital Category by Institute for Biotechnology and Medicine Industry. The winning topic is known as "Biological reconstruction technology, Thoughtful medical services-- Leading globally pioneer in treating osteosarcoma patients."

Professor Wei-Ming Chen said that on the basis of experimental osteosarcoma study, his research team has discovered a significant result. They found the gene mutation sequence among human mesenchymal stem cells and osteosarcoma cancer, a new milestone for gene therapy. From clinical observation, blood osteosarcoma patents are more likely to transfer cancer cell if went through massage therapy. The research team use mouse mode for basic research, and got a clinically confirmed result on this observed phenomenon. In addition, because of malignant bone cancer mostly occurs in children and adolescence, Professor Chen with the patient's family founded the "Taiwan Osteosarcoma Caring Association," to give a positive in-depth primary and secondary school teachers and student lectures on the proper guidance of medical concepts, in order to avoid making the same mistakes, lead to amputation and lung metastasis tragedy. Professor Chen also giving material assistance and emotional care for patient care in order to achieve all-round care for the body, mind, and spirit.

Professor Chen said in the past for osteosarcoma patients, amputation is the only option to survive. In recent years, with advances in chemotherapy, osteosarcoma tumor resection without the need for amputation of limb salvage reconstructive surgery (limb salvage procedure) has gradually become the mainstream treatment. But the research team found that with increasing length of survival of patients with this type of tumor, the artificial joint that the patients wearwould gradually loosen. The patient then must once again undergo the surgery and will possibly hurt the residual bone, and the final result in patients requiring prolonged wheelchair walker. Professor Chen's mentor, vice president of TPEVGH, Tain-Hsiung Chen, in January 1991 first introduced vitro irradiation (extracorporeal irradiation) autologous bone reconstructive surgery, which you cut the cancer bone first and then administration of high-dose radiation exposure in vitro to kill tumor cells. Lastly replanted back the bone into the body, the results are satisfied. The research team also began in 2005 with the use of liquid nitrogen cryogenic freezing to remove tumor cells, concurrent now appropriate antifreeze protection, and liquid nitrogen freezing method can more effectively protect the cartilage. At present, the use of these technologies has been quite skillful, accumulated experience more attractive to foreign physicians comes to learn.

Professor Chen said he was grateful to the rich resources provided by the school and TPEVGH , which helped the team obtain strong research capabilities to solve clinical problems encountered. Professor Chen believes:"Keep the bone equal to keep the patient's future". No matter how hard the process of medical care is, as long as it's the best long-term prognosis for patients, they will stick to it. At present, the patients with osteosarcoma in TPEVGH have accounted for more than 60% of the total number of cases in Taiwan. The number of cases using biological treatment with autologous bone reconstruction of malignant bone tumors accumulated, has gone far beyond the world of other hospitals. According to the literature, TPEVGH currently has the lowest rate of complications in patients with osteosarcoma and functional recovery force the best in the world.

Professor Chen (right 4) and his team win a 17th National Biotechnology & Medical Care Quality Award

Professor Chen (right 4) and his team win a 17th National Biotechnology & Medical Care Quality Award


views